YOLFTbeta
Urteste SA

Urteste SA

URT · WAR · Healthcare / Biotechnology

43.00PLN+0.80 (+1.90%)

Price History

Full chart

Market Stats

Previous Close42.20
Open41.80
Day Range41.10 – 44.60
52-Week Range24.00 – 72.20
Volume780
Market Cap65.62M
P/E (TTM)0.00
Forward P/E0.00
EPS-4.94
Dividend Yield0.00%
Beta0.20
50-Day Avg43.47
200-Day Avg46.20

About

Urteste S.A. engages in the research and development of diagnostic tests for cancers in Poland. It offers diagnostic tests for pancreas, prostate, kidney, colon, liver, biliary tract, bile ducts, stomach, lung, esophagus, ovary, endometrium, blood, breast, and brain. The company was incorporated in 2021 and is based in Gdansk, Poland.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Grzegorz Stefanski
  • Employees38
  • Headquartersul. Starodworska 1, Gdansk, Poland, 80-137, Poland
  • Websitehttps://urteste.eu

Leadership

  • Mr. Grzegorz StefanskiPresident of the Management Board
  • Mr. Tomasz KostuchMember of the Management Board

Financials

Income Statement

Currency: PLN2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue0003.00K1.33M1.80M22.00K
Growth (%)----+44233.33%+35.34%-98.78%
Cost of Revenue30.36K14.84K116.61K291.00K479.00K298.00K322.00K
Gross Profit-30.36K-14.84K-116.61K-288.00K-479.00K1.50M-322.00K
Gross Margin----9600.00%-36.02%83.44%-1463.64%
Operating Expense334.38K1.21M4.07M3.84M5.97M5.68M8.21M
Operating Income-364.74K-1.22M-4.19M-4.13M-6.45M-4.17M-8.53M
Operating Margin----137666.67%-484.74%-231.89%-38759.09%
EBITDA-363.94K-1.21M-4.12M-3.57M-5.67M-3.11M-8.21M
EBITDA Margin----119066.67%-426.47%-172.78%-37295.45%
Net Income-364.74K-530.22K-2.32M-4.06M-5.59M-3.63M-5.98M
Net Income Margin----135333.33%-420.00%-201.72%-27186.36%
R&D-977.00K1.45M2.59M5.55M2.58M2.19M
R&D as % of Total Revenue---86266.67%417.67%143.56%9977.27%
Interest Expense17.555.67K16.0251.00K570.00K545.00K205.00K
Interest Expense % of Total Revenue---1700.00%42.86%30.28%931.82%

Balance Sheet

Currency: PLN2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.24M1.38M9.94M6.69M29.60M29.62M45.14M
Total Liabilities44.02K18.21K252.04K1.07M1.85M5.51M10.56M
Total Equity1.20M674.33K9.69M5.62M27.74M24.11M24.93M
Cash173.26K427.35K8.53M3.43M1.14M1.46M8.84M
Total Debt--710.00K597.00K627.00K415.00K2.98M
Net Debt-173.26K-427.35K-7.82M-2.84M-512.00K-1.05M-5.87M

Cash Flow

Currency: PLN2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-398.48K-1.35M-2.57M-3.79M-5.32M-5.47M10.64M
Investing Cash Flow-38.26K-42.22K-656.39K-1.19M-24.40M6.23M-9.41M
Financing Cash Flow610.00K1.65M11.34M-113.00K27.43M-444.00K6.15M
Capital Expenditure38.26K42.22K656.39K1.19M1.74M8.96M231.00K
Free Cash Flow-436.74K-1.40M-3.23M-4.99M-7.07M-14.43M10.41M
FCF to OCF109.60%103.12%125.51%131.45%132.75%263.86%97.83%

Earnings

Report DateDec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026
EPS Estimate------------------
EPS Actual-0.66-0.84-1.03-0.64-1.00-1.25-1.47-0.91-0.79-0.94-0.39-0.27-0.97-0.52-1.19-1.19-1.34-1.22
Surprise------------------
Timing------------------

Key Statistics & Ratios

Market Cap65.62M
Enterprise Value61.57M
Trailing P/E0.00
Forward P/E0.00
Price / Sales23.67
Price / Book2.71
EPS-4.94
Book Value14.62
Revenue (TTM)2.77M
Gross Profit (TTM)2.54M
EBITDA-2.14M
Profit Margin-130.38%
Operating Margin239.66%
Return on Equity-16.02%
Return on Assets-6.09%
Shares Outstanding1.53M
Shares Float384.10K
Beta0.20
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%